Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 11Sarcoma 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neoplasms 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Inflammatory Breast Neoplasms 1HR Positive HER2 Negative Advanced Breast Cancer 1HER-2 Positive Breast Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

pembrolizumab 12Cisplatin 5Cetuximab 5Paclitaxel 4durvalumab 3Nivolumab 3Ipilimumab 3Gemcitabine 3Cyclophosphamide 3poly ICLC 2avelumab 2Radiation 2Pemetrexed 2Leucovorin 2Irinotecan 2Fluorouracil 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tislelizumab 1tirbanibulin 1spartalizumab 1sonidegib 1sitravatinib 1repotrectinib 1pralsetinib 1pertuzumab 1pepinemab 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma × eribulin × Clear all
NCT01554371 2021-02-03

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

University of California, San Francisco

Phase 1/2 Completed
44 enrolled 14 charts
Breast

Breast Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡